Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
 - EconoTimes)
NEW ORLEANS, Sept. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 23, 2017 to file lead plaintiff applications in a securities class action lawsuit against Teva Pharmaceutical Industries Limited (NYSE:TEVA), if they purchased the Company’s American Depository Shares (“ADSs”) and/or shares on the Tel Aviv Stock Exchange between November 15, 2016 and August 2, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Pennsylvania.
Get Help
Teva Pharmaceutical investors should visit us at https://www.claimsfiler.com/cases/view-teva-pharmaceutical-industries-ltd-american-depository-shares-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Teva Pharmaceutical and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 3, 2017, Teva disclosed the recording of a goodwill impairment charge of $6.1 billion for Q2 2017 related to the acquisition of Actavis Generics as a result of poor performance in its U.S. generics sector, as well as lower overall expected poor performance due to increased competition and delays in product launches.
On this news, the price of Teva Pharmaceutical’s shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
